{"organizations": ["Ltd", "BioMed Inc"], "uuid": "8f063abd19698601e080358d71a6f78fe0005767", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.bio-medicine.org", "main_image": "", "site_section": "http://feeds.bio-medicine.org/latest-biology-technology", "section_title": "Latest Biology Technology from Bio-Medicine.Org", "url": "http://www.bio-medicine.org/biology-technology-1/Q-BioMed-Inc--Enters-into-Partnership-with-the-Strategic-and-Scientific-Advisory-Firm-Wombat-Capital--Ltd--34326-1/", "country": "US", "title": "Q BioMed Inc. Enters into Partnership with the Strategic and Scientific Advisory Firm Wombat Capital, Ltd.", "performance_score": 0, "site": "bio-medicine.org", "participants_count": 0, "title_full": "Q BioMed Inc. Enters into Partnership with the Strategic and Scientific Advisory Firm Wombat Capital, Ltd.", "spam_score": 0.0, "site_type": "news", "published": "2015-10-13T16:57:00.000+03:00", "replies_count": 0, "uuid": "8f063abd19698601e080358d71a6f78fe0005767"}, "author": "", "url": "http://www.bio-medicine.org/biology-technology-1/Q-BioMed-Inc--Enters-into-Partnership-with-the-Strategic-and-Scientific-Advisory-Firm-Wombat-Capital--Ltd--34326-1/", "ord_in_thread": 0, "title": "Q BioMed Inc. Enters into Partnership with the Strategic and Scientific Advisory Firm Wombat Capital, Ltd.", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Date:10/13/2015 \nNEW YORK , October 13, 2015 /PRNewswire/ -- \nQ BioMed Inc (OTC: QBIO), a biotechnology acceleration and development company, has entered into a strategic relationship with Wombat Capital, Ltd., a New York and Paris, France based strategic and scientific advisory firm.. \nThis collaborative arrangement gives Q BioMed and its stakeholders access to a highly respected scientific advisory team as well as long established pharmaceutical industry relationships. The advisors within the Wombat team are opinion leaders and experts in their respective fields and provide significant experience and expertise to the Q BioMed business development objectives. \nMore information can be found on the Q BioMed website under Scientific Advisors http://qbiomed.com/about-us/scientific-advisors/ \nJean-Jacques (John) Mondoloni , President of Wombat Capital, Ltd. said, \"We are very pleased to be working with Q BioMed and their team. We believe there is great opportunity in their plan to bring private and small life sciences assets through the development pipeline and we look forward to assisting in any way we can.\" \nQ BioMed CEO, Denis Corin said, \"We are privileged to have access to such a broad-based and highly experienced team of industry experts. We look forward to working with Jean-Jacques and his team in vetting and sourcing high value assets for Q BioMed.\" \nAbout Q BioMed Inc. \nQ BioMed Inc. \"Q\" is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need‚Äè. \nForward-Looking Statements: \nThis press release may contain \"forward-looking statements\" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. \nContact:", "external_links": [], "published": "2015-10-13T16:57:00.000+03:00", "crawled": "2015-10-14T16:19:49.785+03:00", "highlightTitle": ""}